Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Fig. 1

a FDG-PET/CT in December 2012, prior to BRAF inhibitor therapy, showed intensely FDG avid lesions in the orbit, the parotid glad and the lung post AdCD40L treatment. b PET/CT in May 2013, after the initiation of the treatment with vemurafenib, showed that all the previously described intensely FDG avid lesions had lower SUVmax uptake. Physiologic FDG uptake in right posterior vocal cord is observed. Black arrow: metastasis in right parotid gland. White arrow: metastasis in right orbit. Striped arrow: lung metastasis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us